Efficacy of combined autologous of bone marrow and peripheral blood The International Journal of Cell Cloning on hematological recovery following high-dose chemotherapy

1992 ◽  
Vol 10 (S1) ◽  
pp. 168-170
Author(s):  
T. Mukaiyama ◽  
M. Ogawa ◽  
Bone Marrow
Keyword(s):  
Bone Marrow ◽  
Peripheral Blood ◽  
High Dose Chemotherapy ◽  
High Dose ◽  
Cell Cloning

GM-CSF potentiated peripheral blood progenitor cell (PBPC) collection with or without bone marrow as hematologic support of high-dose chemotherapy: Two protocols

1991 ◽  
Vol 20 (S1) ◽  
pp. S25-S29 ◽  
Author(s):  
Anthony D. Elias ◽  
Rosemary Mazanet ◽  
Cathy Wheeler ◽  
Ken Anderson ◽  
Lois Ayash ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Peripheral Blood ◽  
Progenitor Cell ◽  
High Dose Chemotherapy ◽  
Peripheral Blood Progenitor Cell ◽  
High Dose ◽  
Gm Csf

scholarly journals Bone marrow reconstitution after high-dose chemotherapy and autologous peripheral blood progenitor cell transplantation: Effect of graft size

1994 ◽  
Vol 5 (9) ◽  
pp. 795-802 ◽  
Author(s):  
E. van der Wall ◽  
D.J. Richel ◽  
M.J. Holtkamp ◽  
I.C.M. Slaper-Cortenbach ◽  
C.E. van der Schoot ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Cell Transplantation ◽  
Peripheral Blood ◽  
Progenitor Cell ◽  
High Dose Chemotherapy ◽  
Peripheral Blood Progenitor Cell ◽  
High Dose ◽  
Graft Size

Use of autologous bone marrow cells following high-dose chemotherapy (HDCT) for patients (pts) with recurrent lymphoma in whom stem cell harvesting from the peripheral blood was inadequate

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 8124-8124
Author(s):  
G. Kumaran ◽  
J. Murray ◽  
D. Sweeney ◽  
E. Liakopoulou ◽  
J. A. Radford
Keyword(s):  
Bone Marrow ◽  
Stem Cell ◽  
Peripheral Blood ◽  
Bone Marrow Cells ◽  
Autologous Bone Marrow ◽  
High Dose Chemotherapy ◽  
Severe Neutropenia ◽  
High Dose ◽  
Stem Cell Rescue ◽  
Non Hodgkin Lymphoma

8124 Background: HDCT with autologous stem cell rescue (ASCR) is an established treatment for recurrent Hodgkin and non- Hodgkin lymphoma (HL, NHL) but some of these pts fail to mobilise adequate numbers of CD34+ cells from the peripheral blood (PB). Harvest of bone marrow (BM) stem cells and use of these alone or in combination with PB derived cells is an option but there are concerns about feasibility and outcome. Methods: 29 pts who had HDCT after failed PB stem cell harvest between July 1999 and December 2005 were studied in terms of CD34+ cell yield (PB and BM), transfusion dependence, engraftment and survival. Results: There were 17 males and 12 females (median age 49yrs, range 19–66) with recurrent HL (n=16) or NHL (n=13). All had received at least 2 lines of chemotherapy (10 pts =3) and 7 had received radiotherapy (5 mediastinal, one neck and one abdominal field). Mobilisation of CD34+ cells from PB was attempted using chemotherapy followed by filgrastim. 22 pts proceeded to leukapheresis on the basis of predictive CD34+ counts (median collects 2; range 0–4) with a median total collect of 0.98×106 CD34+cells/kg (range 0.03–1.84). Subsequently, all pts had a BM harvest producing a median collect of 1.63x106 CD34+cells/kg (range 0.45–4.75). 29 pts then received BEAM/CBV followed by re-infusion of PB+BM cells except in 7 pts where only BM cells were available. In 26/29 pts surviving to day 100; total CD34+ cells infused, 2.37×106/kg (range 1.73- 5.0), time to neutrophils >0.5×109/L, 12 days (range 9–23), platelet units transfused, 6 (range 0–24), red cells units transfused 6 (range 0–18) (all medians). 2 pts continued to have red cell transfusions beyond day 100. 3/29 pts died due to severe neutropenia/septicaemia at days 23–25 (treatment related mortality 10.3%); the CD34+ dose received by these pts was 1.97×106/kg in 2 and 1.84×106/kg in 1. Beyond day 100, 9 pts have died from HL/NHL and 2 are lost to follow-up. Conclusions: In patients with HL/NHL who fail to mobilise adequate numbers of CD34+ cells from PB, a BM harvest can produce a combined BM/PB collect capable of producing haemopoeitic reconstitution following HDCT without excessive toxicity. No significant financial relationships to disclose.

Both early and committed haemopoietic progenitors are more frequent in peripheral blood than in bone marrow during mobilization induced by high-dose chemotherapy + G-CSF

1995 ◽  
Vol 91 (3) ◽  
pp. 535-543 ◽  
Author(s):  
Corrado Tarella ◽  
Giovanni Benedetti ◽  
Daniele Caracciolo ◽  
Claudia Castellino ◽  
Cristina Cherasco ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Peripheral Blood ◽  
High Dose Chemotherapy ◽  
High Dose

Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: a randomized comparison.

1995 ◽  
Vol 13 (6) ◽  
pp. 1328-1335 ◽  
Author(s):  
J Beyer ◽  
N Schwella ◽  
J Zingsem ◽  
I Strohscheer ◽  
I Schwaner ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Progenitor Cells ◽  
Peripheral Blood ◽  
Germ Cell Tumors ◽  
Autologous Bone Marrow ◽  
High Dose Chemotherapy ◽  
High Dose ◽  
Transfusion Independence ◽  
Transfusion Requirements ◽  
Peripheral Blood Progenitor Cells

PURPOSE To compare autologous bone marrow (BM) with peripheral-blood progenitor cells (PBPC) as hematopoietic rescue after high-dose chemotherapy (HDCT). PATIENTS AND METHODS From January 1991 until April 1993, 47 consecutive patients with relapsed or refractory germ cell tumors were randomized to either BM harvest or collection of PBPC mobilized by chemotherapy plus granulocyte colony-stimulating factor (G-CSF). After additional conventional-dose salvage treatment, all patients received HDCT with carboplatin 1,500 mg/m2, etoposide 2,400 mg/m2, and ifosfamide 10 g/m2 with either BM or PBPC rescue. RESULTS Forty-six patients were assessable for hematologic reconstitution, and one patient died on day +4 before engraftment. Rescue using PBPC resulted in a significantly shorter recovery time to neutrophil counts more than 500/microL (10.0 v 11.0 days, P < .01), neutrophil counts more than 1,000/microL (10.0 v 12.0 days, P = .001), and platelet counts more than 20,000/microL (10.0 v 17.0 days, P < .01), as well as in fewer days to transfusion independence from RBCs (8.0 v 12.0, P < .05) and platelets (9.0 v 12.0, P < .01) and fewer days of intravenous (IV) antibiotics (9.0 v 11.0, P < .05). However, no statistical differences in transfusion requirements or in other clinical outcome variables were observed. Overall survival and event-free survival also were not different in the two study arms. CONCLUSION We conclude that the use of PBPC mobilized by chemotherapy plus G-CSF results in sustained trilineage reconstitution after HDCT, which occurs more rapidly as compared with BM. The earlier hematologic reconstitution in patients with PBPC rescue significantly reduces the time to transfusion independence.

scholarly journals Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy

Blood ◽  
1993 ◽  
Vol 81 (7) ◽  
pp. 1709-1719
Author(s):  
WP Peters ◽  
G Rosner ◽  
M Ross ◽  
J Vredenburgh ◽  
B Meisenberg ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Progenitor Cells ◽  
Resource Utilization ◽  
Peripheral Blood ◽  
High Dose Chemotherapy ◽  
Hospital Charges ◽  
High Dose ◽  
Colony Stimulating Factor ◽  
Gm Csf ◽  
Stimulating Factor

Two hematopoietic colony-stimulating factors, granulocyte colony- stimulating factor (G-CSF) and granulocyte-macrophage CSF (GM-CSF), have been shown to accelerate leukocyte and neutrophil recovery after high-dose chemotherapy and autologous bone marrow (BM) support. Despite their use, a prolonged period of absolute leukopenia persists during which infections and other complications of transplantation occur. We collected large numbers of peripheral blood (PB) progenitors after CSF administration using either G-CSF or GM-CSF and tested their ability to affect hematopoietic reconstitution and resource utilization in patients undergoing high-dose chemotherapy and autologous BM support. Patients with breast cancer or melanoma undergoing high-dose chemotherapy and autologous BM support were studied in sequential nonrandomized trials. After identical high-dose chemotherapy, patients received either BM alone, with no CSF; BM with either G-CSF or GM-CSF; or BM with G-CSF or GM-CSF and G-CSF or GM-CSF primed peripheral blood progenitor cells (PBPC). Hematopoietic reconstitution, as well as resource utilization, was monitored in these patients. The use of CSF- primed PBPC led to a highly significant reduction in the duration of leukopenia with a white blood cell (WBC) count under 100 and 200 cells/mL, and neutrophil count under 100 and 200 cells/mL with both GM- and G-CSF primed PB progenitor cells, compared with the use of the CSF with BM or with historical controls using BM alone. In addition, the use of CSF-primed PBPC resulted in a significant reduction in median number of antibiotics used, days in the Bone Marrow Transplant Unit, and hospital resources used. Patients receiving G-CSF primed PBPC also experienced a reduction in the median number of days in the hospital, red blood cell (RBC) transfusions, platelet transfusions, days on antibiotics, and discounted hospital charges. Phenotypic analysis of the CSF-primed PBPC indicated the presence of cells bearing antigens associated with both early and late hematopoietic progenitor cells. The use of CSF-primed PBPC can significantly improve hematopoietic recovery after high-dose chemotherapy and autologous BM support. In addition, the use of G-CSF-primed PBPC was associated with a significant reduction in hospital resource utilization, and a reduction in hospital charges.

Sign in / Sign up

Export Citation Format

Share Document